Cancer Immunotherapy Market Size, Share, Growth, and Industry Analysis, By Type (Melanoma,Colorectal cancer,Prostate cancer,Head and neck cancer,Breast cancer,Lung cancer,Other), By Application (Hospitals,Clinics,Others), Regional Insights and Forecast to 2035

Cancer Immunotherapy Market Overview

The global Cancer Immunotherapy Market size is projected to grow from USD 51130.61 million in 2026 to USD 56192.55 million in 2027, reaching USD 288654.22 million by 2035, expanding at a CAGR of 9.9% during the forecast period.

The global cancer immunotherapy market was valued at approximately USD 129.5 billion in 2024. North America held over 45.2 % of the global market share in 2024. The monoclonal antibodies therapy type represented the largest share, at about 64.97 % in North America in 2024. The lung cancer application comprised the largest application segment globally, about 34.5 % of market share. The hospitals & clinics end user segment held nearly 59.5 % of global market share.

In the USA, the cancer immunotherapy market size was about USD 50.19 billion in 2023. The United States accounted for approximately 92.70 % of North America’s cancer immunotherapy market in 2024. The American monoclonal antibodies therapy type share in the America cancer immunotherapy market was about 45.55 % in 2024. Lung cancer represented about 26.53 % of the America market by cancer type in 2024. Hospitals and clinics together captured approximately 65.62 % of America’s cancer immunotherapy market share in 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Incidence of cancer segment accounts for about 94.10 % share of immunotherapy drugs market in 2023 globally.
• Major Market Restraint: North America holds the largest share (42.6 %) for immunotherapy drugs market in 2025, limiting growth opportunities in other regions due to concentration.
• Emerging Trends: Monoclonal antibodies projected to hold about 33.3 % of therapy type share in 2025.
• Regional Leadership: North America projected to hold about 44.3 % of the market share in 2025.
• Competitive Landscape: In America market, monoclonal antibodies led with 45.55 % share in 2024, cell-based therapies growing fast.
• Market Segmentation: Lung cancer holds 34.5 % of global application share; breast cancer about 24.2 % in 2025.
• Recent Development: United States accounted for 92.70 % of North America’s market in 2024; new approvals of therapies such as CAR-T.

Cancer Immunotherapy Market Latest Trends

The Cancer Immunotherapy Market Trends are being shaped by rising global incidence of cancer, particularly lung, breast, colorectal, melanoma, and prostate cancers. Lung cancer leads with 34.5 % of application share globally. Breast cancer is anticipated to hold about 24.2 % share in 2025. Therapy type trends show monoclonal antibodies dominating, with about 33.3 % share among therapy types in 2025; immune checkpoint inhibitors and adoptive cell therapies are increasingly part of the pipeline. Route of administration is shifting: oral immunotherapy treatments are expected to capture about 49.7 % of route share in 2025. Regional trends show North America dominating with roughly 44.3 % share in 2025, while Asia-Pacific is rising due to high cancer burden: Asia recorded about 9,503,710 new cancer cases and 5,809,431 deaths in 2023, making it the region with the highest disease burden. Patient preference, regulatory approvals, investment in R&D, and adoption of biomarker-based personalized therapies are becoming more visible: cancer immunotherapy industry research reports highlight growing funding—U.S. invested over USD 7.22 billion in cancer research in 2024; Europe allocated about USD 4.75 billion to health programs including immunotherapy in 2023. There is also increasing development of novel modalities like neoantigen-based vaccinations, bispecific antibodies, oncolytic virus therapies, immune system modulators, and cell therapies. Hospital and clinic end-users remain dominant, capturing nearly 59.5-65.6 % share in many markets.

Cancer Immunotherapy Market Dynamics

The Cancer Immunotherapy Market Dynamics explore the underlying forces that are shaping the industry, including demand drivers, market restraints, emerging opportunities, and operational challenges. Rising global cancer incidence of more than 19 million new cases annually, strong R&D pipelines, and increasing adoption of checkpoint inhibitors are accelerating growth. At the same time, barriers such as high treatment costs, regulatory complexity, and limited infrastructure in emerging economies continue to restrict access. Opportunities in personalized medicine, biomarker-driven therapies, and innovative delivery methods such as oral and subcutaneous formats are reshaping the landscape. By analyzing these dynamics, stakeholders gain actionable insights into the Cancer Immunotherapy Market Growth, Cancer Immunotherapy Market Outlook, and Cancer Immunotherapy Market Opportunities across different regions and therapeutic categories.

DRIVER

"Rising cancer incidence and unmet treatment needs."

The global incidence of cancer has reached over 19 million new cases annually; in 2023 Asia alone reported 9,503,710 new cancer cases. In the United States, nearly 1.8 million new cases and 606,520 deaths were reported in 2020. The rising burden of cancers such as lung, breast, colorectal, melanoma, and prostate is fueling demand for advanced immunotherapy. The monoclonal antibody therapies led with ~71.5 % revenue share globally in 2024 among product types like immune checkpoint inhibitors, oncolytic virus therapy, cancer vaccines, immunomodulators, etc. High number of approvals by regulatory authorities in USA, Europe, China is increasing access. Strong investments: U.S. allocated USD 7.22 billion in cancer research in 2024. Asia Pacific governments increased healthcare spending (for example India’s health budget rose over 13 % in fiscal 2023-24 to about USD 10.8 billion in cancer and health sector components).

RESTRAINT

"High treatment costs and access barriers."

Many immunotherapy treatments including monoclonal antibodies, CAR-T cell therapies, and adoptive cell therapies involve costly manufacturing, complex cold-chain logistics, and high per patient treatment expenses. Access in emerging markets is limited by these costs. In America, although monoclonal antibodies had 45.55 % share in 2024, cell-based therapies (which are more expensive) face capacity constraints. Insurance reimbursement policies are inconsistent across regions; in developing countries, out-of-pocket expenditure remains high. Regulatory approval timelines, clinical trial costs, and safety concerns (e.g. immune-related adverse events) add to delays. Infrastructure limitations (specialized facilities for cell therapies, skilled personnel) are also restraining faster adoption in Asia-Pacific and Middle East & Africa.

OPPORTUNITY

Growth in personalized and precision immunotherapies.

The push toward biomarker-guided therapies (PD-1 / PD-L1, CTLA-4, tumor mutation burden, neoantigens) is creating opportunity. Neoantigen-based vaccines and individualized immunotherapies are under heavy R&D. Advances in route of administration (e.g. oral, subcutaneous) show promise: the oral route is expected to hold about 49.7 % share in 2025. Combination therapies (immunotherapy + chemotherapy / radiation) and new therapeutic classes (oncolytic virus, immune system modulators) are entering clinical pipelines. Also technology improvements (liquid biopsies, better diagnostics) are enabling earlier treatment. Rising healthcare investment in Asia-Pacific opens large patient populations.

CHALLENGE

"Safety, regulatory hurdles, and manufacturing complexity."

Immune-related adverse events remain common in checkpoint inhibitors and CAR-T therapies; managing these side effects requires specialized care. Clinical trial failures are costly: many candidates do not pass late-stage trials. Regulatory requirements differ between jurisdictions; harmonization is slow. Manufacturing of cell therapies (especially autologous CAR-T) faces capacity constraints; achieving consistent quality, purity, scale is challenging. Cold chain and logistics complexity for biologics also raise cost and risk. In less developed regions, lack of infrastructure and skilled staff limits adoption. Reimbursement still uncertain in many markets; payers often demand long follow-up data.

Cancer Immunotherapy Market Segmentation

The Cancer Immunotherapy Market Segmentation provides a structured breakdown of the industry based on type of cancer and application setting, highlighting how therapies are utilized in real-world oncology care. Segmentation by type covers melanoma, colorectal, prostate, head and neck, breast, lung, and other cancers, each reflecting distinct disease prevalence, patient demographics, and treatment adoption rates. Lung cancer dominates with about 34.5 % global share, followed by breast cancer at nearly 24.2 %, while other cancers such as kidney, ovarian, and hematological malignancies are expanding through CAR-T and novel biologics. By application, hospitals capture the largest market share at 59.5–65.6 %, supported by advanced infrastructure, while clinics and ambulatory centers are emerging as key access points for outpatient immunotherapy. This segmentation analysis allows businesses to evaluate Cancer Immunotherapy Market Size, Cancer Immunotherapy Market Share, and Cancer Immunotherapy Market Insights by focusing on the highest-impact patient populations and care delivery channels.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Melanoma: Melanoma immunotherapy has been one of the earliest success stories for immune checkpoint inhibitors. Checkpoint inhibitors targeting PD-1 and CTLA-4 have demonstrated survival benefits in advanced melanoma patients, with response rates exceeding 40 % in many clinical settings. Globally, melanoma represents approximately 7.5–8 % of immunotherapy market share by cancer type. In North America, adoption is particularly high, with melanoma accounting for over 10 % of immunotherapy utilization. Hospitals are the primary end-users, administering combination regimens. Clinical trials indicate durable responses lasting over 5 years for some patients, creating long-term demand in this segment.
• Colorectal Cancer: Colorectal cancer is the third most common cancer worldwide, with more than 1.9 million new cases in 2023 and about 930,000 deaths globally. Immunotherapy adoption in colorectal cancer is concentrated in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) patients, who represent around 15 % of colorectal cancer cases. This group responds well to PD-1 inhibitors. Colorectal cancer accounts for about 6–7 % of the cancer immunotherapy market globally. In Europe, colorectal cancer is the second leading cause of cancer death, driving strong demand for targeted immunotherapies. Hospitals and specialty oncology centers play a key role in administration.
• Prostate Cancer: Prostate cancer is among the top cancers in men, with over 1.4 million new cases worldwide in 2023. Immunotherapy adoption in prostate cancer has been slower compared to melanoma or lung cancer, largely due to limited biomarker-based eligibility and modest response rates. Currently, prostate cancer immunotherapy market share is estimated at 4–5 % globally, but novel vaccines and CAR-T cell therapies targeting prostate-specific membrane antigen (PSMA) are in development. North America accounts for the largest share, where prostate cancer incidence is high, representing about 20 % of all cancers in men. Hospitals are key channels, especially in U.S. where clinical trials are concentrated.
• Head and Neck Cancer: Head and neck squamous cell carcinoma (HNSCC) affects approximately 930,000 people annually worldwide. Immunotherapies targeting PD-1 (such as nivolumab and pembrolizumab) have approval in recurrent or metastatic settings, where traditional chemotherapy has limited effectiveness. Head and neck cancer represents around 5 % of cancer immunotherapy market share globally. In Asia-Pacific, incidence is particularly high due to tobacco and betel nut use, making the region a critical market for expansion. Hospitals dominate treatment, but specialized oncology clinics are increasingly engaged in immunotherapy administration in urban centers.
• Breast Cancer: Breast cancer is the most commonly diagnosed cancer worldwide, with about 2.3 million new cases reported in 2023 and around 685,000 deaths. Triple-negative breast cancer (TNBC) is the major immunotherapy target, representing 10–15 % of all breast cancer cases. Immunotherapy treatments, particularly PD-1/PD-L1 inhibitors, are increasingly used in combination with chemotherapy. Breast cancer is projected to hold about 24.2 % share of the global cancer immunotherapy market in 2025, making it the second largest segment after lung cancer. Adoption is strongest in North America and Europe, where early diagnosis and biomarker testing rates are higher. Hospitals administer the majority of these therapies.
• Lung Cancer: Lung cancer leads all cancer immunotherapy applications globally, with about 2.5 million new cases in 2023 and nearly 1.8 million deaths, representing the highest cancer mortality worldwide. Lung cancer accounts for about 34.5 % share of the cancer immunotherapy market, the largest among all types. In the U.S., lung cancer immunotherapy held approximately 26.53 % of the cancer immunotherapy market in 2024. Immunotherapy drugs like PD-1/PD-L1 inhibitors dominate treatment protocols, often in combination with chemotherapy or targeted therapies. Hospitals are the main settings for administration, with growing adoption in Asia-Pacific where lung cancer incidence is rising due to smoking prevalence and pollution exposure.
• Other Cancers: The “other” cancers category includes kidney, ovarian, bladder, pancreatic, and hematological cancers. Collectively, these represent about 10–15 % of the global immunotherapy market. Bladder cancer, for example, has shown significant responsiveness to immunotherapies, with checkpoint inhibitors approved for advanced stages. Pancreatic cancer, though historically resistant, is seeing new clinical trial activity combining checkpoint inhibitors with other modalities. Hematological cancers such as certain leukemias and lymphomas are major beneficiaries of CAR-T cell therapies, where durable remissions are reported in up to 50 % of patients in specific indications.

BY APPLICATION

• Hospitals: Hospitals dominate the cancer immunotherapy market, holding approximately 59.5–65.6 % of market share globally. In the U.S., hospitals accounted for 65.62 % of the immunotherapy market in 2024. Hospitals manage administration of intravenous monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapies, which require specialized facilities and multidisciplinary teams. Hospitals also support clinical trials, patient monitoring, and long-term follow-ups, making them the backbone of immunotherapy adoption. The increasing hospital infrastructure investments in Asia-Pacific and Middle East are further driving this segment.
• Clinics: Clinics are the second major segment, accounting for approximately 25–30 % of global cancer immunotherapy applications. Clinics are particularly relevant for outpatient administration of immunotherapies, especially PD-1/PD-L1 inhibitors and certain subcutaneous or oral therapies. The convenience of clinics appeals to patients requiring regular treatment cycles without hospitalization. Clinics are growing fastest in Europe and Asia, where specialized oncology clinics are being developed. Their share is expected to expand with the rise of oral and subcutaneous formulations, reducing the reliance on hospitals for every treatment cycle.
• Others: The “others” segment, which includes ambulatory care centers, cancer research institutes, and home-based care programs, contributes about 10–12 % of the global immunotherapy market. Ambulatory centers provide cost-effective access in developed countries. Cancer research institutes play a major role in clinical trials, representing a niche but essential part of the segment. With the rise of telemedicine and digital health, some immunotherapy follow-ups and monitoring are being extended to home-based settings, particularly in the U.S. and Europe. This segment, while smaller, reflects future opportunities for decentralized care models.

Regional Outlook for the Cancer Immunotherapy Market

The Cancer Immunotherapy Market Regional Outlook provides a comparative perspective on geographic performance, analyzing market share distribution across North America, Europe, Asia-Pacific, and Middle East & Africa. Regional differences are driven by cancer incidence rates, healthcare infrastructure, regulatory frameworks, and investment levels. North America remains the clear leader with more than 45 % of global share, supported by strong R&D pipelines, high adoption rates, and advanced healthcare facilities. Europe follows with significant government funding and robust clinical trial activity, while Asia-Pacific is rapidly expanding with over 9.5 million new cancer cases annually and increasing healthcare investments. Middle East & Africa, although smaller, are experiencing growth through oncology centers, government spending, and medical tourism. Understanding regional leadership, market size distribution, and localized opportunities helps B2B stakeholders forecast Cancer Immunotherapy Market Trends, evaluate Cancer Immunotherapy Market Forecast, and identify high-growth geographies for strategic expansion.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominated the global cancer immunotherapy market in 2024, holding over 42.6 % share and about 45.2 % share of the global total. The United States alone represented around 92.70 % of North America’s market in 2024. Monoclonal antibodies were the leading therapy type in North America, with ~64.97 % share in 2024. Lung cancer in America accounted for approximately 26.53 % share by cancer type in 2024. Hospitals & clinics captured around 65.62 % of America’s market share. The U.S. cancer immunotherapy market in 2023 stood at about USD 50.19 billion.

The North America Cancer Immunotherapy Market is forecasted to reach USD 47,180.2 million in 2025, expanding to USD 110,332.6 million by 2034, registering a CAGR of 9.8 %, and maintaining the largest global share of over 42 %, primarily driven by high cancer incidence, early adoption of immune checkpoint inhibitors, advanced healthcare infrastructure, and strong R&D funding pipelines from both private and public institutions.

North America – Major Dominant Countries in the Cancer Immunotherapy Market

• United States: Expected market size of USD 43,741.3 million in 2025, with a projected expansion to USD 101,936.1 million by 2034, capturing 92.7 % of regional share at a CAGR of 9.8 %, driven by high immunotherapy adoption in lung and breast cancer.
• Canada: Forecasted market size of USD 2,188.7 million in 2025, increasing to USD 5,032.3 million by 2034, holding about 4.6 % of the North American market at a CAGR of 9.7 %, with growth supported by universal healthcare adoption programs.
• Mexico: Market size estimated at USD 1,250.2 million in 2025, projected to achieve USD 2,891.5 million by 2034, representing 2.7 % of regional share with a CAGR of 9.9 %, reflecting rising access to immunotherapies in urban cancer centers.
• Puerto Rico: Expected market size of USD 713.1 million in 2025, projected to rise to USD 1,648.5 million by 2034, contributing 1.5 % of the regional share at a CAGR of 9.8 %, mainly through hospitals and clinical trials.
• Dominican Republic: Anticipated to reach USD 547.0 million in 2025, growing to USD 1,224.2 million by 2034, holding nearly 1.2 % of share with CAGR 9.7 %, supported by improving cancer treatment facilities.

EUROPE

Europe is a significant market with growing adoption of cancer immunotherapies. Government funding in Europe’s health programs was about USD 4.75 billion in 2023, including immunotherapy initiatives. In Germany, cancer care expenditure reached about USD 40.1 billion in 2023. Regulatory agencies are providing accelerated approvals for novel immunotherapies. European patients have increasing access to checkpoint inhibitors, monoclonal antibodies, and cancer vaccines. Breast cancer and lung cancer are significant application types. Hospital and clinics dominate end-user share.

The Europe Cancer Immunotherapy Market is expected to achieve USD 29,931.2 million in 2025, expanding to USD 70,267.1 million by 2034, registering a CAGR of 9.9 %, with around 26.6 % of global market share, supported by government-led oncology funding, high clinical trial activity, and widespread hospital infrastructure that facilitates advanced immunotherapy adoption.

Europe – Major Dominant Countries in the Cancer Immunotherapy Market

• Germany: Forecasted market size of USD 7,422.5 million in 2025, increasing to USD 17,444.9 million by 2034, contributing 24.8 % of European share at a CAGR of 9.8 %, with dominance in lung and breast cancer immunotherapy.
• United Kingdom: Market size expected at USD 5,153.2 million in 2025, projected to grow to USD 12,055.1 million by 2034, holding 17.2 % of share with CAGR 9.9 %, reflecting strong adoption of PD-1/PD-L1 inhibitors.
• France: Estimated market size of USD 4,838.1 million in 2025, expanding to USD 11,316.5 million by 2034, capturing 16.1 % share at CAGR 9.8 %, driven by robust hospital-based immunotherapy programs.
• Italy: Market size projected at USD 3,742.2 million in 2025, reaching USD 8,754.9 million by 2034, holding 12.5 % of regional share with a CAGR of 9.9 %, supported by early-stage trial participation and government cancer care initiatives.
• Spain: Market size expected at USD 3,170.5 million in 2025, projected to grow to USD 7,412.6 million by 2034, representing 10.6 % of share at CAGR 9.8 %, fueled by rising cancer patient population and expanded immunotherapy reimbursement.

ASIA-PACIFIC

Asia-Pacific is emerging rapidly. In 2023, Asia reported 9,503,710 new cancer cases and 5,809,431 deaths, making it region with highest disease burden. Local companies in China and India are engaging in development and partnerships. Hospitals and clinics are expanding capacity. The share of Asia-Pacific in global market is rising from lower double digits toward high teens or low twenties. Oral and subcutaneous delivery formats are particularly relevant due to infrastructure constraints.

The Asia Cancer Immunotherapy Market is projected to be valued at USD 25,003.9 million in 2025, reaching USD 60,148.4 million by 2034, recording the fastest growth among regions with a CAGR of 10.1 %, supported by a rapidly growing patient pool, increasing cancer incidence exceeding 9.5 million new cases annually, and accelerated healthcare investments across China, India, and Japan.

Asia – Major Dominant Countries in the Cancer Immunotherapy Market

• China: Market size projected at USD 10,491.6 million in 2025, rising to USD 25,247.9 million by 2034, capturing 41.9 % of Asia share with CAGR 10.3 %, supported by rapid drug approvals and expanding oncology infrastructure.
• India: Expected market size of USD 4,825.9 million in 2025, projected to achieve USD 11,625.4 million by 2034, representing 19.3 % of share at CAGR 10.2 %, fueled by high head and neck cancer prevalence and strong healthcare funding.
• Japan: Market size of USD 4,320.2 million in 2025, expected to reach USD 10,293.6 million by 2034, capturing 17.3 % of Asia share with CAGR 10.0 %, driven by innovation in clinical trials and adoption of checkpoint inhibitors.
• South Korea: Market size forecasted at USD 2,755.7 million in 2025, expanding to USD 6,610.3 million by 2034, holding 11.0 % share with CAGR 9.9 %, reflecting strong government support for precision oncology.
• Australia: Market size projected at USD 2,610.5 million in 2025, increasing to USD 6,071.2 million by 2034, accounting for 10.4 % share with CAGR 10.0 %, driven by advanced hospital care and robust immunotherapy research collaborations.

MIDDLE EAST & AFRICA

Middle East & Africa market is smaller but expanding. Key countries like Saudi Arabia, South Africa, UAE are increasing allocation for oncology research and immunotherapy procurement. Saudi Arabia dedicated USD 50.4 billion to healthcare in 2023, part for oncology & immunotherapy. Access to checkpoint inhibitors is growing. Government policies are setting up oncology centres; medical tourism for cancer care including immunotherapy is being promoted. Regional share remains modest, likely single digit percentages of global market.

The Middle East & Africa Cancer Immunotherapy Market is forecasted at USD 10,220.8 million in 2025, projected to reach USD 21,903.6 million by 2034, with a CAGR of 9.5 %, representing nearly 9 % of global market share, supported by growing medical tourism, rising cancer awareness, and government funding for oncology infrastructure.

Middle East & Africa – Major Dominant Countries in the Cancer Immunotherapy Market

• Saudi Arabia: Market size estimated at USD 3,215.2 million in 2025, projected to grow to USD 6,874.4 million by 2034, capturing 31.4 % of regional share with CAGR 9.6 %, driven by healthcare spending and oncology center expansion.
• United Arab Emirates: Expected market size of USD 1,870.1 million in 2025, projected to reach USD 4,012.9 million by 2034, holding 18.3 % share with CAGR 9.5 %, fueled by strong medical tourism demand.
• South Africa: Market size forecasted at USD 1,540.6 million in 2025, increasing to USD 3,239.4 million by 2034, representing 15.1 % share with CAGR 9.4 %, supported by improved cancer screening and treatment access.
• Egypt: Estimated market size of USD 1,276.4 million in 2025, projected to achieve USD 2,684.5 million by 2034, capturing 12.5 % of share at CAGR 9.5 %, with growth driven by hospital adoption of checkpoint inhibitors.
• Turkey: Market size of USD 1,088.5 million in 2025, expected to expand to USD 2,392.4 million by 2034, representing 10.6 % share with CAGR 9.6 %, reflecting its role as a regional hub for oncology treatments.

List of Top Cancer Immunotherapy Companies

• Peregrine Pharmaceuticals
• Hoffman La-Roche
• Immunomedics
• Merck
• Amgen
• Eli Lilly and Company
• AstraZeneca
• Seattle Genetics
• Pfizer
• Novartis
• Bayer AG
• Bristol-Myers Squibb
• Janssen Global Services
• Viralytics Ltd

64. Hoffman La-Roche: Roche is a global leader in the cancer immunotherapy market, with monoclonal antibodies representing over 64.97 % share in North America in 2024. The company dominates lung and breast cancer segments, supported by multiple FDA-approved checkpoint inhibitors.

Merck: Merck holds one of the largest shares globally through Keytruda (pembrolizumab), contributing significantly to lung cancer immunotherapy, which accounts for 34.5 % of the global market. In 2024, Merck remained the U.S. leader with strong adoption in hospitals and clinics.

Investment Analysis and Opportunities

Investment in cancer immunotherapy is increasing globally. The United States invested about USD 7.22 billion in cancer research in 2024. Europe’s allocation for health programs including immunotherapy was about USD 4.75 billion in 2023. Asia-Pacific markets like China and India are increasing health R&D budgets too; India alone allocated approximately USD 10.8 billion to health sector investments including cancer care in fiscal 2023-24. Investors are showing interest in biotech firms developing monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, oncolytic virus therapies, and neoantigen-based therapies.

New Product Development

Innovation is accelerating in cancer immunotherapy product development. Neoantigen-based cancer vaccines are under heavy research. Oncolytic virus therapies are being developed with improved delivery systems. Immune system modulators and combination therapies (immune checkpoint inhibitors plus vaccines or oncolytic viruses) are in clinical trials. Orally administered immunotherapy treatments are expected to hold about 49.7 % of route share in 2025. Subcutaneous and intratumoral delivery formats are also being explored. Monoclonal antibodies remain dominant, accounting for about 64.97 % share among therapy types in North America in 2024. New monoclonal antibodies targeting PD-1, PD-L1, CTLA-4 are being designed.

Five Recent Developments

• In 2024, monoclonal antibodies held ~71.51 % of global product type revenue share among cancer immunotherapies.
• Approval in December 2024 of Imfinzi (durvalumab) in the U.S. for treating adult patients with small cell lung cancer whose disease had not progressed after concurrent platinum chemotherapy and radiation therapy.
• In 2024, the United States accounted for 92.70 % of North America cancer immunotherapy market share.
• Oral route of administration expected to capture about 49.7 % share in 2025.
• Asia reported about 9,503,710 new cancer cases and 5,809,431 cancer deaths in 2023.

Report Coverage of Cancer Immunotherapy Market

The Cancer Immunotherapy Market Report covers a broad scope: includes therapy types such as monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, oncolytic virus therapy, immune system modulators. It covers routes of administration like oral, intravenous, subcutaneous, intratumoral. The report includes applications: lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. End-user segmentation: hospitals, clinics, cancer research centres, others. Geographic coverage spans North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Cancer Immunotherapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 51130.61 Million in 2026
Market Size Value By	USD 288654.22 Million by 2035
Growth Rate	CAGR of 9.9% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Melanoma Colorectal cancer Prostate cancer Head and neck cancer Breast cancer Lung cancer Other By Application : Hospitals Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample